AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

- RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1

- Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis1,2

- A new oral solution of RINVOQ was approved for use in patients with pJIA1

- RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases1

NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.1

"The European Commission's approval of RINVOQ for pJIA expands the treatment options available to pediatric patients and their families, offering the potential for remission, improvements in pain and physical function," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "RINVOQ's new indication continues to build on our differentiated immunology portfolio with breadth and depth across therapeutic areas and patient populations."

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and is estimated to impact approximately 126,000 children in Europe.3 pJIA is a subtype of JIA and is characterized by inflammation in five or more joints – including the small joints of the hands and feet and large joints like the knees, hips and ankles – that persists for at least six weeks in children and adolescents.4,5 This disease can be painful and debilitating and, if left untreated, may lead to joint damage.3,6 Ongoing disease activity in pJIA is common, with persistent symptoms or flares affecting many patients into adulthood.6-8

Data Supporting the EC Approval

The EC approval of RINVOQ for pJIA is supported by the SELECT-YOUTH study and data from adult patients with rheumatoid arthritis. The SELECT-YOUTH study is a single-arm, open-label, global, Phase 1 study evaluating the pharmacokinetics, efficacy, safety and tolerability of RINVOQ in patients ages 2 to 18 years.1,2

RINVOQ demonstrated efficacy as early as week 12, with response rates improving through week 48, as shown below.1,2 The efficacy observed in children with pJIA was generally consistent with responses in adult patients with rheumatoid arthritis.1

Functional ability, as measured by C-HAQ, improved, with a mean change from baseline of −0.46 (n=115) at week 12 and −0.64 (n=108) at week 48. Pain scores also improved, with a mean change from baseline of −26.2 (n=116) at week 12 and −30.8 (n=109) at week 48. C-HAQ and pain data are reported as observed.2

In the study, no new safety risks were identified.9 The rate of treatment-emergent adverse events (TEAEs) was 499.6 events per 100 patient-years (E/100 PY). The rate of serious adverse events was 10.2 E/100 PY. The rate of TEAEs that led to discontinuation of the study drug was 2.7 E/100 PY. No cases of major cardiovascular or thrombotic events, malignancies or deaths were reported during the study period.2 No negative impact on growth or development was observed.9

"The SELECT-YOUTH results underscore that clinical remission for children with pJIA is not a rare hope but a critical and achievable outcome that helps reduce the risk of permanent joint damage in some of our youngest, most vulnerable patients," said Prof. Dr. Gerd Horneff, head of the Department of General Pediatrics, Asklepios Clinic, Sankt Augustin, Germany. "The approval of RINVOQ in active pJIA provides a new oral systemic treatment option for patients suffering from this often-debilitating condition."

RINVOQ is also approved in the European Union for the treatment of adults and adolescents with atopic dermatitis, non-segmental vitiligo and alopecia areata and for adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease and giant cell arteritis.1

About the SELECT-YOUTH Study

The SELECT-YOUTH (M15-340) study is a single-arm, open-label, global, Phase 1 study to evaluate the pharmacokinetics, efficacy, safety and tolerability of upadacitinib in patients with polyarticular course juvenile idiopathic arthritis (pcJIA), ages 2 to 18 years. This study consists of three parts: Part 1 consisted of a seven-day multiple-dose pharmacokinetic evaluation, after which patients in Parts 2 and 3 of the trial received a low dose of upadacitinib (equivalent to 15 mg) by using either a twice-daily oral solution or once-daily extended-release tablet based on their body weight and ability to swallow tablets. For more detailed information on this study, please visit clinicaltrials.gov (NCT03725007).

About RINVOQ® (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,10 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1

Indications

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis

RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis

RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata

RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo

RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications

RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use

RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;

- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);

- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)

Use in patients 65 years of age and older

Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available.

Hylenr Completes Phase 1 LCF Reactor Validation at Texas A&M University

Phase 1 testing identified key thermal, noble-gas and material signatures in the Lattice Confinement Fusion (LCF) reactor, with Hylenr now advancing to Phase 2 studies focused on reproducibility, quantitative measurement and commercialization.

HYDERABAD, India, Sept. 22, 2026 /PRNewswire/ -- Hyderabad based Deeptech company Hylenr today announced the completion of Phase 1 of an independent validation study of Lattice Confinement Fusion (LCF), conducted at Texas A&M University, marking an important step in the company's efforts to independently evaluate its lattice-based energy technology and advance its roadmap toward commercialization.

The validation study focused on the Hylenr BRT-NiUCS-2 reactor, a small modular system based on hydrogen-loaded nickel-palladium catalyst materials. Multiple devices and catalyst samples were prepared and tested under controlled laboratory conditions in the Nuclear Engineering Department at Texas A&M University.

Titled 'Validation of Anomalous Heat and Nuclear Signatures in the BRT-NiUCS-2 Reactor: Phase 1 LCF Investigation', the research examined the reactor's thermal performance, radiation emissions, residual gas composition, and post-reaction material characteristics. The Phase 1 research paper, co-authored by Hylenr and Texas A&M University, was presented at the 27th International Conference on Condensed Matter Nuclear Science (ICCF-27), held in Niagara Falls, Canada, from August 31 to September 4.

"Our objective has always been to move beyond internal observations and subject the technology to rigorous, independent testing. The validation study conducted at Texas A&M University provides an important external data point across thermal measurements, gas analysis, and material characterization," said Ram Ramaseshan, Co-Founder and CEO, Hylenr. "These results provide a basis for the next phase of validation while reinforcing our focus on reproducibility, quantitative measurement, and scientific transparency."

Prof. Lin Shao, Professor of Nuclear Engineering at Texas A&M University said, "The Phase 1 research provided an opportunity to examine the BRT-NiUCS-2 reactor using a range of complementary analytical techniques. The combination of thermal measurements, residual gas analysis, nuclear diagnostics and post-reaction materials characterization broadens the experimental basis for assessing the observed phenomena and determining priorities for further investigation."

Among the principal diagnostics was Residual Gas Analysis (RGA), conducted using an SRS RGA 100 system under high-vacuum conditions. The study observed elevated helium, argon and neon signals in the active reactor relative to background measurements, with helium and argon signals reported at levels approximately two to three orders of magnitude above background. No corresponding increase in nitrogen was observed, providing evidence against atmospheric leakage as the sole explanation for the measurements.

Thermal measurements using thermocouples and calibrated infrared imaging also showed the active reactor operating at consistently higher temperatures than the calibration device under comparable input-power conditions. The study further reported post-reaction morphological and compositional changes in catalyst samples based on SEM/EDX analysis.

Radiation monitoring using Geiger–Müller and neutron detectors found no detectable gamma or X-ray emissions, while neutron counts remained statistically indistinguishable from background during the approximately five-day monitoring period.

Hylenr will now move toward Phase 2, focusing on testing multiple independent reactors, quantitative calorimetry and improved characterization of loading parameters, alongside isotopic-ratio measurements and advanced analytical techniques including SIMS and ICP-MS.

The company views this staged validation process as a critical bridge between laboratory observations and eventual commercialization, with future development aimed at establishing repeatability, quantifying energy output and defining the engineering requirements for scalable systems.

About Hylenr

Hylenr develops small, modular energy systems using hydrogen-loaded materials and lattice confinement. Its research focuses on material transformation and excess-heat phenomena under controlled conditions, progressing these findings through independent validation toward potential commercial energy applications.

SOURCE HYLENR

Share this article

Temu Strengthens Support for Romanian Businesses in Collaboration with ABSL

BUCHAREST, Romania, Sept. 22, 2026 /PRNewswire/ -- Temu has signed a Memorandum of Understanding (MoU) with the Association of Business Service Leaders in Romania (ABSL), the country's leading organization representing the business services sector.

The partnership will see Temu take part in ABSL's programs and events, engaging directly with ABSL's community, a network spanning startups to multinational companies operating in shared services, business process outsourcing, IT outsourcing, and R&D.

Temu will also contribute expertise and in-kind support to ABSL's initiatives, reflecting Temu's commitment to becoming a trusted, active participant in Romania's business ecosystem.

"We welcome Temu as an ABSL E-commerce Partner. This collaboration reflects the growing importance of cross-sector cooperation and creates new opportunities to connect expertise from the business services and e-commerce sectors," said Adrian Baron, President of ABSL Romania. "It also provides a valuable platform for dialogue and the exchange of perspectives, supporting the continued development of the broader business community in Romania."

This collaboration aligns with Temu's broader efforts to support local businesses in Europe and address key barriers to growth like complexity, cost, and lack of connection cited by trade associations, chambers of commerce, and industry bodies during discussions with Temu this year.

"Romania has a vibrant business community and we want to help them grow," said a Temu spokesperson. "Through the collaboration with ABSL, we hope to contribute to the business ecosystem in Romania."

Businesses interested in selling on Temu can apply through the seller portal at seller.temu.com.

About Temu

Temu is a global e-commerce platform connecting consumers with millions of manufacturers, brands and business partners. Operating in more than 90 markets worldwide, Temu is committed to providing affordable, high-quality products that enable customers to live better lives.

About ABSL

The Association of Business Service Leaders in Romania (ABSL) is a leading organization representing the business services sector in Romania, gathering high profile companies which conduct business in the area of Shared Services Center (SSC), Business Process Outsourcing (BPO), Information Technology Outsourcing (ITO), Research and Development (R&D) and companies contributing to the sector's growth.

The Association pursues its objectives by fostering collaboration within the sector, conducting industry research, promoting both the industry and the opportunities Romania has to offer, and working closely with public authorities to support the sector's continued development.

ABSL Romania's activities are structured around several key areas: organizing best-practice sharing and networking events, developing industry studies and practical guides, promoting Romania as an investment destination, delivering educational initiatives, and engaging in government relations.

ABSL Romania's community brings together both Romanian and multinational companies, including regional and global leaders in the business services industry.

Share this article

Panel to be Moderated by Sabio Advisor Caleb Pearson, Featuring McDonald's Global Media Lead Michelle Niblock

LOS ANGELES, Sept. 22, 2026 /PRNewswire/ -- Creator TV®, the first creator-led streaming network and content studio owned by Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF), today announced that Co-Founder and General Manager Joe Ochoa will join a panel at Marketecture Live on September 23 in Chicago to discuss how sports fandom is changing, the evolving roles of creators, and what it means for the brands trying to reach these audiences.

The session, "Sports Influence Looks Different Now: Where Creators and Fandom Meet," is scheduled as a breakout at 1:45 p.m. CT. The panel will be moderated by Caleb Pearson, Advisor to Sabio Holdings with over 20 years of marketing and media leadership experience, including his time as Vice President at McDonald's, where he led Media, CRM, Loyalty, Digital, and Customer Experience. His prior leadership roles include Grubhub and Citi. Michelle Niblock, McDonald's Global Media Lead and US Digital Lead at Publicis Groupe, will also be joining the panel.

Sports fandom has fundamentally changed. Creators, athletes, social media and the data behind it all have made it personal, year-round and always on, driving growth well beyond the broadcast alone. The session will explore how brands are adapting their media strategies as audiences move fluidly between live broadcasts, streaming platforms and creator content, and why the biggest opportunities often exist beyond traditional sports media.

"We've seen firsthand what happens when you put creators at the center of a live sports moment," said Joe Ochoa, Co-Founder and General Manager at Creator TV®. "People don't just watch, they show up and stay engaged long after the event ends. This is what real community building looks like, and it's something brands should be paying attention to."

Ochoa's appearance follows a string of live moments for Creator TV Sports™, including the debut of the Creator Pickleball Tour at VidCon Anaheim earlier this year, as the company continues to build out its live, creator-driven sports programming.

This panel comes as Creator TV continues to experience rapid growth. The platform's audience is up 4.8x year to date, from January through August 2026, and hit 305,000 unique viewers in August, marking a new record high. Average monthly audience is also up 138% in 2026 compared to 2025. According to an audience analysis from Sabio's App Science®, Creator TV viewers are 2.5x more likely to stream sports content, underscoring the crossover between creator audiences and sports fandom the panel will explore.

Marketecture Live brings together marketing, media and advertising leaders for a day of programming on where the industry is headed. More information on the event is available at https://chicago.marketecturelive.com.

About Creator TV®

Creator TV® is a creator-led entertainment company operating at the intersection of the creator economy, television, and advertising. We build live, in-person, and digital experiences that turn shared passions into real community, bringing creators and audiences together around the moments shaping culture today. Our content studio develops and produces original formats and franchises distributed across major streaming TV and social platforms. For brands, Creator TV offers authentic ways to engage those communities through content, live experiences, CTV advertising, and creator marketing. Distributed across Plex, Xumo Play, Amazon Fire TV Channels and more, Creator TV® is headquartered in Los Angeles and owned and operated by Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF), an award-winning leader in connected television advertising technology. Learn more at creatortv.com.

About Sabio

Sabio Holdings (TSXV: SBIO, OTCQB: SABOF) is a technology and services leader in the fast-growing ad-supported streaming space. Its cloud-based, end-to-end technology stack works with top blue-chip, global brands and the agencies that represent them to reach, engage, and validate (R.E.V.) streaming audiences. Sabio consists of a proprietary ad-serving technology platform, App Science™, a non-cookie-based SaaS analytics and insights platform with AI natural language capabilities, and Creator TV®, the first creator-led streaming network and content studio. For more information, visit sabioctv.com.

Contact:

Investor Relations

Sajid Premji, Chief Financial Officer, [email protected], 1.844.974.2662 

SOURCE Sabio Inc.

Share this article

GOTHENBURG, Sweden and SUNNYVALE, Calif., Sept. 22, 2026 /PRNewswire/ -- Accenture (NYSE: ACN) and Google Cloud today announced that Volvo Cars has become the lead industry partner for Horizon, an open-source software development platform that helps car makers and automotive suppliers build, test, and deploy software for Android Automotive Operating System (AAOS) more efficiently.

Horizon brings together cloud-native development tools, virtual testing environments, and AI-assisted workflows into a unified platform. This helps car makers and automotive suppliers develop and deliver high-quality software at speed and make engineering more productive.

As Horizon's lead industry partner, Volvo Cars is migrating its global AAOS software development environment to the Horizon platform. The platform will give its engineers access to faster development workflows, virtual testing environments and AI-assisted software development tools, freeing engineering teams to spend more time building in-car experiences.

"We're building some of the most complex products in the world, which requires a development environment built to match," said Gregor Zetsche, Head of Connected Experience at Volvo Cars. "As Horizon's lead industry partner, we can directly solve our toughest engineering challenges and empower our teams to deliver new experiences faster than ever."

Volvo Cars is the lead car maker working with Accenture and Google Cloud to bring the Horizon platform to the industry. Insights from this collaboration will help refine the platform and expand its generative AI capabilities for automotive companies and other industrial manufacturers.

Accelerating connected software development

Modern vehicles increasingly offer digital experiences, such as navigation, media, voice assistants, connected services and over-the-air software updates. As consumers expect these experiences to become richer and more sophisticated throughout a vehicle's lifetime, manufacturers need faster and more efficient ways to build, test, and validate the software that enables improvements at scale.

For car makers and the wider automotive industry, the Horizon platform addresses these challenges by offering:

- An up to 9x faster software testing using virtual Cuttlefish-based Android Automotive environments, that enable large-scale testing with agentic AI.

- A reduction of infotainment feature development costs by up to 40%.

- Intelligent caching and optimized build pipelines significantly reduce software build times: Instead of waiting up to two hours, engineers can get feedback within minutes.

- Remote access to virtual and physical device farms allows developers worldwide to build and validate software from anywhere, while reducing infrastructure requirements. This improves hardware utilization and reduces the amount of costly physical test equipment required.

- Virtual workbenches are speeding up the onboarding of new developers. Instead of waiting weeks for physical specialized hardware and investing additional hours for the setup, engineers can instantiate their environments in seconds.

"Horizon enables a faster, more flexible and efficient way to deliver software-defined vehicle features. Its standardized, repeatable and scalable processes help deliver reliable, high-quality software products, while significantly reducing time to market," said Juergen Reers, Global Automotive & Mobility Lead, Accenture. "Horizon will allow Volvo Cars' engineers to focus on what matters most: creating differentiated vehicle experiences and continuously delivering new value to drivers through software at high speed."

"Software now defines the automotive brand," said Henry Bzeih, Global Director, Automotive Industry, Google Cloud. "Horizon on Google Cloud gives Volvo Cars the ability to move faster while releasing high-quality software and features on a cadence that matches the expectations of modern mobility. This is how next generation digital experiences reach drivers at agile speed."

Accenture and Google Cloud, with Volvo Cars as leading industry partner, are already working with other automotive and industrial organizations to extend the reach of Horizon into further companies and markets.

About Accenture

Accenture helps the world's leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed for organizations across industries. Our strategy is to be the reinvention partner of choice for our clients and lead in the safe, widespread adoption of AI, and to be the most client-focused, AI-enabled, great place to work in the world. We bring together the talent of our approximately 799,000 people with proprietary assets and platforms, deep process and industry expertise, and leading ecosystem relationships to deliver end-to-end solutions and measurable outcomes at scale. Through our Reinvention Services, we offer broad expertise across Cybersecurity, Digital Core, Finance, Industry and Enterprise, Song, Supply Chain and Engineering, and Talent, with advanced capabilities in AI and Data, Industry and Process, and Technology. We serve approximately 9,000 clients and generated approximately $70 billion in FY25 revenue. Visit us at accenture.com.

About Google Cloud

Google Cloud offers a powerful, optimized AI stack—including AI infrastructure, leading models like Gemini, data management capabilities, multicloud security solutions, developer tools and platform, as well as agents and applications—that enables organizations to transform their business for the Agentic Era. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

SOURCE Google Cloud

Share this article

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to June 24, 2026

DEADLINE: October 5, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew its timeline for CVS Caremark formulary and coverage approval decisions for neffy faced issues. The Company's commercialization plans would be impacted by this delay. Based on these facts, ARS's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's David Schwartz is a founding partner of Schall Brown & Schwartz LLP, and his primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Share this article

UWM Holdings Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UWMC

NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against UWM Holdings Corporation ("UWM" or "the Company") (NYSE: UWMC) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of UWMC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to August 5, 2026

DEADLINE: October 13, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. UWM created an excess hedging risk by deviating from its strategy of not hedging its mortgage servicing rights. Based on these facts, UWM's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Share this article

UWMC Investors Have Opportunity to Lead UWM Holdings Corporation Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Sept. 22, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UWM Holdings Corporation ("UWM" or "the Company") (NYSE: UWMC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of UWMC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: March 9, 2026 to August 5, 2026

DEADLINE: October 13, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. UWM moved away from its traditional strategy by taking a major hedge position against its mortgage servicing rights. The Company created an excess hedging risk through its actions. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UWM, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

SOURCE Schall, Brown & Schwartz LLP

Share this article

Skanska to build a data center in Georgia, USA, worth USD 84M, about SEK 780M

STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- Skanska has signed a contract with an existing client to begin work on a data center in Georgia, USA. The contract is worth USD 84M, about SEK 780M, which will be included in the US order bookings for the third quarter of 2026.

The project includes the construction of an approximately 22,700 square-meter (244,730-SF) data center with five colocation data halls and administrative space designed for 48 MW capacity. Delivery includes all civil, structural, utilities, electrical, mechanical, security, interior amenities, and fit-out, as well as commissioning of major equipment through completion.

Work will begin in November 2026 and is expected to be completed in the third quarter of 2028.

For further information please contact:

Ashley Jeffery, Head of Communications, Skanska USA Building, +1 813 459 3682

Andreas Joons, Press Officer, Skanska AB, tel +46 76 870 75 51

Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at www.skanska.com/group.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE Skanska

Share this article

Massachusetts Institute of Technology replaces Princeton after a 15-year streak atop National Universities as U.S. News introduces a major outcomes-based metric and expands rankings eligibility.

Summary

- MIT named No. 1 National University, replacing Princeton after a 15-year run at the top spot.

- New "Earnings by Major" metric introduced to evaluate graduate return on investment four years post-graduation.

- Expanded eligibility yields a record number of ranked schools, plus new rankings for in-state value and undergraduate economics.

- $5,000 scholarship sweepstakes live from Sept. 22 alongside access to 13,000+ financial aid awards.

WASHINGTON, Sept. 22, 2026 /PRNewswire/ -- Massachusetts Institute of Technology (MIT) has taken the No. 1 spot among National Universities in the U.S. News & World Report 2027 Best Colleges rankings, replacing Princeton University in the top position it held consecutively since the 2012 edition.

Rounding out the top positions in the National Universities category are Princeton University (No. 2) and Harvard University (No. 3). Meanwhile, Williams College again earned the top ranking among National Liberal Arts Colleges in the 42nd edition evaluating nearly 1,700 institutions.

Addressing "Is College Worth It?" with Earnings by Major

The 2027 edition introduces significant methodology changes designed to address growing public concerns regarding higher education affordability and long-term value. Chief among these is the new Earnings by Major ranking factor, which evaluates graduate earnings four years post-graduation using data from the U.S. Department of Education's College Scorecard.

By focusing specifically on employed federal financial aid recipients whose highest degree is a bachelor's, this metric minimizes the influence of pre-existing family financial advantages and evaluates institutions on the true value they add. Comparing earnings strictly within specific academic disciplines ensures colleges are evaluated on institutional performance rather than degree-mix concentration in high-paying fields. The Earnings by Major metric replaces the Graduate Indebtedness factor, reflecting a broader shift toward measuring verifiable post-graduate outcomes.

"With families increasingly scrutinizing the true cost and return on investment of a college degree, our goal is to provide clear, actionable data," said LaMont Jones, Ed.D., managing editor for Education at U.S. News. "The 2027 Best Colleges rankings serve as a vital decision-making tool for prospective students and parents, offering transparent metrics on outcomes, affordability and academic quality to help families make fully informed financial and educational investments."

Economic Diversity Among the Top 25

U.S. News rankings also highlight a strong commitment to economic diversity among the nation's top institutions. Among the top 25 National Universities, MIT and Princeton are No. 3 and No. 4, respectively, in the percentage of students receiving Pell Grants. Additionally, Amherst College – the No. 2-ranked National Liberal Arts College – leads in economic diversity among the top 25 Liberal Arts Colleges. See the full list here.

Expanded Eligibility & What's New for 2027

Driven by updates to the Carnegie Classification framework, roughly 20% of previously ranked institutions moved to new U.S. News ranking categories this year. Because these schools are now evaluated against a different peer group, their 2027 rankings cannot be directly compared to prior years. Separately, updates to the Carnegie framework allowed U.S. News to expand eligibility to additional types of institutions previously not included, adding several schools specialized in fields like business, engineering and health to the overall rankings for the first time.

Also new this year:

- New Specialty Rankings: U.S. News has introduced separate undergraduate specialty rankings in Undergraduate Economics.

- Inaugural Best Value Rankings: To complement the longstanding Best Value Schools rankings, the 2027 guide debuts the Best Value Schools for In-State Students, specifically evaluating public universities based on academic quality and regional affordability for residents. University of North Carolina - Chapel Hill is No. 1 in the inaugural ranking.

This edition of the rankings also includes specialized rankings, such as the most innovative colleges, top performers on social mobility and historically Black colleges and universities, as well as universities with the top computer science programs for artificial intelligence.

Top Performers: 2027 Best Colleges

Overall Rankings

National Universities

1. Massachusetts Institute of Technology

2. Princeton University

3. Harvard University

National Liberal Arts Colleges

1. Williams College

2. Amherst College

3 (tie). Bowdoin College

3 (tie). Claremont McKenna College

3 (tie). Pomona College

3 (tie). Swarthmore College

Regional Universities: North

1. Babson College

2. Bentley University

3. Providence College

Regional Universities: South 

1. The Citadel, the Military College of South Carolina

2 (tie). Berry College

2 (tie). Embry-Riddle Aeronautical University - Daytona Beach 

Regional Universities: Midwest

1. John Carroll University

2. Milwaukee School of Engineering

3 (tie). Calvin University

3 (tie). Ohio Northern University

Regional Universities: West 

1. California Polytechnic State University - San Luis Obispo

2. California State Polytechnic University - Pomona

3 (tie). Saint Mary's College of California

3 (tie). University of Redlands, Los Angeles

3 (tie). University of Washington Bothell

Additional Rankings

Public Schools: National Universities

1 (tie). University of California, Berkeley

1 (tie). University of California, Los Angeles

3. University of Michigan – Ann Arbor

Historically Black Colleges and Universities (HBCU)

1. Spelman College

2. Howard University

3. Tuskegee University

Top Performers on Social Mobility: National Universities

1 (tie). Florida International University

1 (tie). University of California, Riverside

3. Oakland City University

Colleges for Veterans: National Universities

1. University of Chicago

2. Cornell University

3 (tie). Brown University

3 (tie). Washington University in St. Louis

Additionally, students can find rankings of programs that enhance student experience, including first-year experiences, co-ops/internships, service learning, study abroad and undergraduate research/creative projects.

Methodology

To rank higher education institutions for its Best Colleges lists, U.S. News categorizes schools by academic mission and geographic region before evaluating them on up to 17 weighted measures of academic quality and success. The methodology heavily emphasizes student outcomes – which make up more than half of a school's total score – focusing on key indicators such as graduation and retention rates, social mobility for low-income students and post-graduate earnings. These performance metrics are combined with factors like academic peer assessment and faculty resources to establish overall composite scores, with U.S. News publishing exact individual ranks for the top 90% of institutions in each category and decile ranges for the remainder.

For prospective students and families navigating the college selection process, an institution recognized in U.S. News' Best Colleges rankings may be worth considering alongside other essential factors, such as location, net price, financial aid availability, campus life and specialized academic programs.

For more information on this and the new metrics, check out the methodologies.

Student Resources 

Beyond those informational resources, U.S. News actively supports families in navigating college costs. To help them offset the rising cost of higher education, U.S. News launched a $5,000 no-essay scholarship sweepstakes, open to prospective students from Sept. 22 on USNews.com. This initiative complements U.S. News' Scholarship Finder tool, which connects students with key financial aid resources and over 13,000 scholarship opportunities.

To order a copy of the "Best Colleges 2027" guidebook (ISBN 979-8-9864591-8-9), visit the online U.S. News store.

For more information, visit Best Colleges and use #BestColleges on Facebook, Instagram, LinkedIn, Threads, TikTok and X.

About U.S. News & World Report

U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, insurance, personal finance, travel, automobiles, real estate, careers and consumer products and services.

SOURCE U.S. News & World Report, L.P.

Share this article